Tobacco smoking, nicotine, and nicotine and non-nicotine replacement therapies.
Tobacco smoking is associated with an increased risk for the development of coronary and pulmonary vascular diseases and smoking cessation will greatly reduce this risk. Nicotine replacement and nonnicotine modalities have been used alone and in combination to help in smoking cessation. These treatment modalities appear to be safe in patients with known stable coronary artery disease.
Frishman
W H
WH
Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA.
Ky
T
T
Ismail
A
A
D000085:Acetates / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000281:Administration, Intranasal; D016642:Bupropion / Q000627:therapeutic use; D002638:Chewing Gum; D003000:Clonidine / Q000627:therapeutic use; D006331:Heart Diseases / Q000453:epidemiology; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D009661:Nortriptyline / Q000627:therapeutic use; D011109:Polymethacrylic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D011145:Polyvinyls / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D018030:Silver Compounds / Q000627:therapeutic use; D012907:Smoking / Q000453:epidemiology; D016540:Smoking Cessation; D061485:Tobacco Use Cessation Devices; D014030:Tobacco, Smokeless
D000085:Acetates; D002638:Chewing Gum; D011109:Polymethacrylic Acids; D011145:Polyvinyls; D018030:Silver Compounds; D016642:Bupropion; C103100:silver acetate; D009538:Nicotine; D009661:Nortriptyline; D003000:Clonidine